Claims for Patent: 9,803,211

Summary for Patent: 9,803,211

Title:	Protein production in transgenic potato plants having suppressed expression of patatin and CD4B
Abstract:	The present disclosure relates to methods and constructs for producing heterologous peptides and proteins in plants in a safe and controlled manner. One aspect of the present invention provides a method of producing heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest and a marker gene, a nucleotide sequence capable of suppressing patatin expression, along with a nucleotide sequence capable of suppressing CD4B expression, and/or a nucleotide sequence capable of overexpressing P19. Another aspect of the invention provides a method of producing a heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest, a marker gene, a transit peptide sequence, and a nucleotide sequence capable of suppressing ADP glucose pyrophosphorylase expression.
Inventor(s):	Peet; Richard C. (Washington, DC), Rommens; Caius (Boise, ID), Chretien; Robert (Danville, VA), Yan; Hua (Boise, ID), Osumi; Teruko (Garden City, ID)
Assignee:	J.R. Simplot Company (Boise, ID)
Application Number:	14/897,164
Patent Claims:	1. A method of producing a heterologous protein or peptide of interest, the method comprising the steps of: a. transforming a potato plant with an expression cassette, the expression cassette comprising (i) a nucleotide sequence capable of suppressing patatin expression; (ii) a nucleotide sequence capable of suppressing CD4B expression wherein the nucleotide sequence capable of suppressing CD4B comprises SEQ ID NO: 5 and SEQ ID NO: 6; (iii) a marker gene; and (iv) a gene coding for a heterologous protein or peptide of interest; b. cultivating the transformed potato plant; and c. extracting the heterologous protein or peptide of interest from the transformed potato plant. 2. The method of claim 1, wherein the nucleotide sequence capable of suppressing patatin expression comprises antisense and sense sequences of patatin as set forth in SEQ ID NO: 3 and SEQ ID: 4. 3. The method of claim 1, wherein the marker gene is selected from a group consisting of GFP, EGFP, GUS, LUX, CAH, SPT, NPTII, HPT, APHIV, BAR, PAT, CHS, AHAS, and flavonoid synthesis genes. 4. The method of claim 1, wherein the protein of interest is selected from a group consisting of interleukin-2, hirudin, insulin, interferons, lactoferrin, hemoglobin, erythropoietin, epidermal growth factor, anthrax vaccines, cholera vaccine, DPT vaccine, hib vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, HPV vaccine, influenza vaccine, Japanese Encephalitis vaccine, MMR vaccine, MMRV vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, polio vaccine, rotavirus vaccine, smallpox vaccine, tuberculosis vaccine, typhoid vaccine, yellow fever vaccine, parvovirus vaccine, distemper vaccine, adenovirus vaccine, parainfluenza vaccine, bordetella vaccine, rabies vaccine, leptospirosis vaccine, lyme vaccine, corona vaccine, round/hookworm vaccine, dewormer vaccine, RNFN vaccine, and HIV vaccine. 5. A method of producing a heterologous protein or peptide of interest, the method comprising the steps of: a. transforming a potato plant with an expression cassette, the expression cassette comprising (i) a nucleotide sequence capable of suppressing patatin expression; (ii) a nucleotide sequence capable of suppressing CD4B expression wherein the nucleotide sequence capable of suppressing CD4B comprises SEQ ID NO: 5 and SEQ ID NO: 6; (iii) a nucleotide sequence capable of overexpressing P19; (iv) a marker gene; and (v) a gene coding for a heterologous protein or peptide of interest; b. cultivating the transformed potato plant; and c. extracting the heterologous protein or peptide of interest from the transformed potato plant. 6. The method of claim 5, wherein the nucleotide sequence capable of suppressing patatin expression comprises antisense and sense sequences of patatin as set forth in SEQ ID NO: 3 and SEQ ID: 4; and wherein the nucleotide sequence capable of overexpressing P19 comprises the P19 sequence as set forth in SEQ ID NO: 2. 7. The method of claim 5, wherein the marker gene is selected from a group consisting of GFP, EGFP, GUS, LUX, CAH, SPT, NPTII, HPT, APHIV, BAR, PAT, CHS, AHAS, and flavonoid synthesis genes. 8. The method of claim 5, wherein the protein of interest is selected from a group consisting of interleukin-2, hirudin, insulin, interferons, lactoferrin, hemoglobin, erythropoietin, epidermal growth factor, anthrax vaccines, cholera vaccine, DPT vaccine, hib vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, HPV vaccine, influenza vaccine, Japanese Encephalitis vaccine, MMR vaccine, MMRV vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, polio vaccine, rotavirus vaccine, smallpox vaccine, tuberculosis vaccine, typhoid vaccine, yellow fever vaccine, parvovirus vaccine, distemper vaccine, adenovirus vaccine, parainfluenza vaccine, bordetella vaccine, rabies vaccine, leptospirosis vaccine, lyme vaccine, corona vaccine, round/hookworm vaccine, dewormer vaccine, RNFN vaccine, and HIV vaccine.

Details for Patent 9,803,211

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	10/20/1997		2033-06-14
Glaxosmithkline Biologicals	HAVRIX	hepatitis a vaccine inactivated	Injection	103475	02/22/1995		2033-06-14
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	02/04/2000		2033-06-14